4.5 Article

Two decades of vaccine innovations for global public good: Report of the Developing Countries' Vaccine Manufacturers Network 20th meeting, 21-23 october 2019, Rio de Janeiro, Brazil

期刊

VACCINE
卷 38, 期 36, 页码 5851-5860

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2020.05.062

关键词

Developing countries; Vaccine manufacturing; Regulatory convergence; Market intelligence; Biotechnology innovation

资金

  1. Bausch Stroebel
  2. Bioengineering
  3. Biozeen
  4. Bosch
  5. GEA Group
  6. GE Healthcare
  7. Gihon
  8. InDevR
  9. Merck Group
  10. Stevanato Group
  11. Rommelag
  12. Sartorius
  13. Temptime Corporation
  14. Tofflon
  15. Univercells
  16. Bill & Melinda Gates Foundation, United States [OPP1204376]
  17. Bill and Melinda Gates Foundation [OPP1204376] Funding Source: Bill and Melinda Gates Foundation

向作者/读者索取更多资源

The Developing Countries' Vaccine Manufacturers Network, joined by global health organizations, held its 20th meeting celebrating two decades of vaccine innovations for global public good. Health leaders from industry, academia and global health organizations reviewed efforts to accelerate innovation, improve access to vaccines, overcome inequalities and strengthen technological and public-health management capabilities. Discussion topics included World Health Organization's immunization strategy, Pan American Health Organization's system-strengthening efforts, Gavi's evaluation of vaccine coverage in middle income countries and developments on public-market intelligence. Health market trends, delivery gaps, integration of system-wide needs, costs and benefits, and implications for stakeholder decision-making were areas of focus. Novel thinking was discussed on integration of policy, financing, regulatory pathways and alignment of innovation priorities to improve efficiency in vaccine development pathways. The Vaccine Innovation Prioritization Strategy collaboration presented nine global innovation priorities, and many other partners and members presented updates on their priorities. Novel technologies and platforms, such as RNA-based vaccines, adenoviral vectors, bioconjugation, blow-fill-seal and two-dimensional barcodes, provided opportunities to accelerate vaccine innovations. Challenges in planning and operations at global level included those in health security, polio eradication, re-emergence of diseases, disparities between forecasts and orders and heterogeneous regulatory requirements. Manufacturers were urged to accelerate innovation and prequalification of high-impact vaccines, such as pneumococcal, human papillomavirus and rotavirus vaccines, to strengthen immunization globally. (C) 2020 The Authors. Published by Elsevier Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据